Slingshot members are tracking this event:

FDA Designates Sangamo's (SGMO) SB-318 an Orphan Drug in Treatment of Mucopolysaccharidosis Type I (MPS I)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 11, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Sb-318, Orphan Drug, Mucopolysaccharidosis Type I, Mps I, Fda